The ARCAD METACER national cohort study of brain metastases in gastro-intestinal cancers.

Advances in Brain Metastases Presented at the American Society of Clinical Oncology 2016 Annual Meeting: Part I

“…Over half of patients received wholebrain radiotherapy (WBRT; 54.1%), with a smaller percentage undergoing surgical resection (17.6%) or SRS (16.0%). While median OS was better in patients who underwent surgical resection, this may merely reflect selection bias [12]. As our understanding of the epidemiology of brain metastases progresses we will be able to provide better patient counseling, make more nuanced decisions in therapeutic management and design clinical trials with a higher likelihood of successfully answering key questions regarding patients with brain metastases.…”